A series of clinical trials published over the last decade have clarified the optimal time to initiate ART in patients being treated for tuberculosis; priority should be given to patients with CD4 <50 cells/mm3 in whom starting ART two weeks after TB treatment reduces mortality by 29% compared with waiting to after eight weeks. This evidence concerns the gene CD4 and tuberculosis.